{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:16:31Z","timestamp":1789193791121,"version":"build-2803163510"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10741-020-10062-w","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T21:02:48Z","timestamp":1610744568000},"page":"861-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis"],"prefix":"10.1007","volume":"26","author":[{"given":"Vasiliki","family":"Bistola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parissis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Foukarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pipitsa N.","family":"Valsamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aris","family":"Anastasakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Koutsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Efthimiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"14","key":"10062_CR1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135(14):1357\u20131377","journal-title":"Circulation"},{"issue":"13","key":"10062_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203\u20131212","journal-title":"Circulation"},{"issue":"2","key":"10062_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2(2):113\u2013122","journal-title":"JACC Heart Fail"},{"issue":"38","key":"10062_CR4","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38(38):2879\u20132887","journal-title":"Eur Heart J"},{"issue":"38","key":"10062_CR5","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585\u201394","journal-title":"Eur Heart J"},{"issue":"24","key":"10062_CR6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"E Gonzalez-Lopez","year":"2017","unstructured":"Gonzalez-Lopez E, Gagliardi C, Dominguez F, Quarta CC, de Haro-Del Moral FJ, Milandri A, Salas C, Cinelli M, Cobo-Marcos M, Lorenzini M, Lara-Pezzi E, Foffi S, Alonso-Pulpon L, Rapezzi C, Garcia-Pavia P (2017) Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 38(24):1895\u20131904","journal-title":"Eur Heart J"},{"issue":"12","key":"10062_CR7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68(12):1323\u20131341","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10062_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.12286","volume":"161","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2013) Systemic amyloidosis in England: an epidemiological study. Br J Haematol 161(4):525\u2013532","journal-title":"Br J Haematol"},{"issue":"20","key":"10062_CR9","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","volume":"3","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, Tsitsilonis O, Kostopoulos I, Terpos E, Dimopoulos MA (2019) Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv 3(20):3002\u20133009","journal-title":"Blood Adv"},{"issue":"2","key":"10062_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bjh.13805","volume":"172","author":"E Kastritis","year":"2016","unstructured":"Kastritis E, Dimopoulos MA (2016) Recent advances in the management of AL amyloidosis. Br J Haematol 172(2):170\u2013186","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10062_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/13506129.2011.574354032","volume":"18","author":"E Kastritis","year":"2011","unstructured":"Kastritis E, Dimopoulos MA (2011) Prognosis and risk assessment in AL amyloidosis\u2013state of the art. Amyloid 18(Suppl 1):89\u201391","journal-title":"Amyloid"},{"issue":"9","key":"10062_CR12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","volume":"99","author":"A Jaccard","year":"2014","unstructured":"Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP (2014) Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 99(9):1479\u20131485","journal-title":"Haematologica"},{"issue":"21","key":"10062_CR13","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66(21):2451\u20132466","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10062_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15(7):387\u2013404","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10062_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s004390050199","volume":"98","author":"DR Jacobson","year":"1996","unstructured":"Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN (1996) Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 98(2):236\u2013238","journal-title":"Hum Genet"},{"issue":"7","key":"10062_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","volume":"336","author":"DR Jacobson","year":"1997","unstructured":"Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336(7):466\u2013473","journal-title":"N Engl J Med"},{"issue":"7","key":"10062_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520\u2013528","journal-title":"Eur Heart J"},{"issue":"10","key":"10062_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10):1286\u20131300","journal-title":"Circulation"},{"issue":"22","key":"10062_CR19","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872\u20132891","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10062_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","volume":"7","author":"S Longhi","year":"2014","unstructured":"Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, Potena L, Leone O, Bartolomei I, Pastorelli F, Salvi F, Rapezzi C (2014) Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging 7(5):531\u2013532","journal-title":"JACC Cardiovasc Imaging"},{"key":"10062_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","volume":"270","author":"L Mohamed-Salem","year":"2018","unstructured":"Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, Hernandez-Vicente A, Reyes-Marle R, Castellon Sanchez MI, Claver-Valderas MA, Gonzalez-Vioque E, Haro-Del Moral FJ, Garcia-Pavia P, Pascual-Figal DA (2018) Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol 270:192\u2013196","journal-title":"Int J Cardiol"},{"issue":"2","key":"10062_CR22","doi-asserted-by":"publisher","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","volume":"2","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ (2013) Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2(2):e000098","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10062_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC (2016) Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133(3):282\u2013290","journal-title":"Circulation"},{"issue":"10","key":"10062_CR24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014\u20131020","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10062_CR25","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Helio T, Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L, Elliott PM (2013) Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(19):1448\u20131458","journal-title":"Eur Heart J"},{"issue":"39","key":"10062_CR26","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"m. Authors, Task Force, Elliott PM,","year":"2014","unstructured":"m. Authors, Task Force, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H, (2014) ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733\u201379","journal-title":"Eur Heart J"},{"issue":"10","key":"10062_CR27","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2017.9236","volume":"318","author":"HI Geller","year":"2017","unstructured":"Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH (2017) Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA 318(10):962\u2013963","journal-title":"JAMA"},{"issue":"2","key":"10062_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/modpathol.2014.102","volume":"28","author":"A Yanagisawa","year":"2015","unstructured":"Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, Kitagawa K, Tasaki M, Misumi Y, Oshima T, Jono H, Obayashi K, Hirakawa K, Uchida H, Westermark P, Ando Y, Mizuta H (2015) Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol 28(2):201\u2013207","journal-title":"Mod Pathol"},{"issue":"17","key":"10062_CR29","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","volume":"72","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M (2018) Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 72(17):2040\u20132050","journal-title":"J Am Coll Cardiol"},{"key":"10062_CR30","doi-asserted-by":"crossref","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164(2):222\u2013228 e1","DOI":"10.1016\/j.ahj.2012.04.015"},{"issue":"4","key":"10062_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3109\/13506129.2013.825240","volume":"20","author":"T Damy","year":"2013","unstructured":"Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V (2013) Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 20(4):212\u2013220","journal-title":"Amyloid"},{"issue":"30","key":"10062_CR32","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799\u20132806","journal-title":"Eur Heart J"},{"issue":"2","key":"10062_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1309\/LYWM47K2L8XYFFB3","volume":"119","author":"RS Abraham","year":"2003","unstructured":"Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA (2003) Quantitative analysis of serum free light chains A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119(2):274\u2013278","journal-title":"Am J Clin Pathol"},{"issue":"13","key":"10062_CR34","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354(13):1362\u20131369","journal-title":"N Engl J Med"},{"issue":"10","key":"10062_CR35","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1038\/bcj.2017.97","volume":"7","author":"O Landgren","year":"2017","unstructured":"Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV (2017) Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10\u201349 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J 7(10):e618","journal-title":"Blood Cancer J"},{"issue":"8","key":"10062_CR36","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.3324\/haematol.2018.190405","volume":"103","author":"A Singh","year":"2018","unstructured":"Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, Castillo JJ, Falk RH (2018) True, true unrelated? Coexistence of Waldenstrom macroglobulinemia and cardiac transthyretin amyloidosis. Haematologica 103(8):e374\u2013e376","journal-title":"Haematologica"},{"issue":"5","key":"10062_CR37","doi-asserted-by":"publisher","first-page":"E141","DOI":"10.1002\/ajh.25440","volume":"94","author":"MH Sidiqi","year":"2019","unstructured":"Sidiqi MH, Dasari S, McPhail ED, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kapoor P, Kourelis T, Leung N, Muchtar E, Grogan M, Lust JA, Kumar S, Kyle RA, Rajkumar VS, Gertz M, Dispenzieri A (2019) Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. Am J Hematol 94(5):E141\u2013E143","journal-title":"Am J Hematol"},{"issue":"1","key":"10062_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","volume":"25","author":"P Phull","year":"2018","unstructured":"Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S (2018) Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid 25(1):62\u201367","journal-title":"Amyloid"},{"issue":"3","key":"10062_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.carpath.2012.09.001","volume":"22","author":"JJ Maleszewski","year":"2013","unstructured":"Maleszewski JJ, Murray DL, Dispenzieri A, Grogan M, Pereira NL, Jenkins SM, Judge DP, Caturegli P, Vrana JA, Theis JD, Dogan A, Halushka MK (2013) Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol 22(3):189\u2013194","journal-title":"Cardiovasc Pathol"},{"issue":"24","key":"10062_CR40","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412","journal-title":"Circulation"},{"issue":"6","key":"10062_CR41","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2215\/CJN.02290508","volume":"3","author":"CA Hutchison","year":"2008","unstructured":"Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P (2008) Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3(6):1684\u20131690","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10062_CR42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","volume":"114","author":"NB Cyrille","year":"2014","unstructured":"Cyrille NB, Goldsmith J, Alvarez J, Maurer MS (2014) Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 114(7):1089\u20131093","journal-title":"Am J Cardiol"},{"issue":"1","key":"10062_CR43","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/openhrt-2015-000289","volume":"3","author":"T Damy","year":"2016","unstructured":"Damy T, Maurer MS, Rapezzi C, Plante-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV (2016) Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart 3(1):e000289","journal-title":"Open Heart"},{"issue":"2","key":"10062_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Plante-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C, Investigators T (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68(2):161\u201372","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10062_CR45","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, Pflugfelder PW, Fox Z, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD (2012) Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 33(9):1120\u20131127","journal-title":"Eur Heart J"},{"issue":"18","key":"10062_CR46","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","volume":"129","author":"CC Quarta","year":"2014","unstructured":"Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH (2014) Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129(18):1840\u20131849","journal-title":"Circulation"},{"issue":"1","key":"10062_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","volume":"49","author":"JD Carroll","year":"1982","unstructured":"Carroll JD, Gaasch WH, McAdam KP (1982) Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation. Am J Cardiol 49(1):9\u201313","journal-title":"Am J Cardiol"},{"issue":"13","key":"10062_CR48","doi-asserted-by":"publisher","first-page":"E1586","DOI":"10.1016\/S0735-1097(12)61587-3","volume":"59","author":"C Quarta","year":"2012","unstructured":"Quarta C, Perlini S, Longhi S, Berardini A, Musca F, Salinaro F, Obici L, Milandri A, Gallo P, Gagliardi C, Biagini E, Mingardi F, Pazzi C, Merlini G, Rapezzi C (2012) A simple voltage\/mass index improves diagnosis of cardiac amyloidosis: an electrocardiographic and echocardiographic study of 570 patients with left ventricular hypertrophy. J Am Coll Cardiol 59(13):E1586","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10062_CR49","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/ehjci\/jeu158","volume":"15","author":"G Di Bella","year":"2014","unstructured":"Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G, Oreto G, Baldari S, Vita G, Khandheria BK, Carerj S (2014) The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging 15(12):1307\u20131315","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"10062_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11886-019-1094-z","volume":"21","author":"D Di Nunzio","year":"2019","unstructured":"Di Nunzio D, Recupero A, de Gregorio C, Zito C, Carerj S, Di Bella G (2019) Echocardiographic findings in cardiac amyloidosis: inside two-dimensional, Doppler, and strain imaging. Curr Cardiol Rep 21(2):7","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10062_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12574-015-0249-1","volume":"13","author":"F Cacciapuoti","year":"2015","unstructured":"Cacciapuoti F (2015) The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis. J Echocardiogr 13(3):84\u201389","journal-title":"J Echocardiogr"},{"issue":"10","key":"10062_CR52","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","volume":"106","author":"D Mohty","year":"2013","unstructured":"Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A (2013) Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 106(10):528\u2013540","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10062_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","volume":"28","author":"OK Siddiqi","year":"2018","unstructured":"Siddiqi OK, Ruberg FL (2018) Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med 28(1):10\u201321","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"10062_CR54","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.echo.2008.11.013","volume":"22","author":"GB Al-Zahrani","year":"2009","unstructured":"Al-Zahrani GB, Bellavia D, Pellikka PA, Dispenzieri A, Hayman SR, Oh JK, Miyazaki C, Miller FA Jr (2009) Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. J Am Soc Echocardiogr 22(3):290\u2013298","journal-title":"J Am Soc Echocardiogr"},{"issue":"19","key":"10062_CR55","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1161\/01.CIR.0000068313.67758.4F","volume":"107","author":"J Koyama","year":"2003","unstructured":"Koyama J, Ray-Sequin PA, Falk RH (2003) Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107(19):2446\u20132452","journal-title":"Circulation"},{"issue":"10","key":"10062_CR56","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.echo.2007.02.025","volume":"20","author":"D Bellavia","year":"2007","unstructured":"Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, Bailey KR, Wood CM, Novo S, Miyazaki C, Miller FA Jr (2007) Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 20(10):1194\u20131202","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"10062_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/13506120902879681","volume":"16","author":"MC Porciani","year":"2009","unstructured":"Porciani MC, Lilli A, Perfetto F, Cappelli F, Massimiliano Rao C, Del Pace S, Ciaccheri M, Castelli G, Tarquini R, Romagnani L, Pastorini T, Padeletti L, Bergesio F (2009) Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid 16(2):63\u201370","journal-title":"Amyloid"},{"issue":"3","key":"10062_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.amjcard.2008.09.102","volume":"103","author":"JP Sun","year":"2009","unstructured":"Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, Merlino JD (2009) Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 103(3):411\u2013415","journal-title":"Am J Cardiol"},{"issue":"2","key":"10062_CR59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","volume":"9","author":"J Ternacle","year":"2016","unstructured":"Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Mohty D, Deux JF, Damy T (2016) Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging 9(2):126\u2013138","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10062_CR60","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","volume":"94","author":"DA Brenner","year":"2004","unstructured":"Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94(8):1008\u20131010","journal-title":"Circ Res"},{"issue":"9","key":"10062_CR61","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 107(9):4188\u20134193","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10062_CR62","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442\u20131448","journal-title":"Heart"},{"issue":"6","key":"10062_CR63","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","volume":"6","author":"D Liu","year":"2013","unstructured":"Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Stork S, Gaudron PD, Knop S, Ertl G, Bijnens B, Weidemann F (2013) Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 6(6):1066\u20131072","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10062_CR64","doi-asserted-by":"publisher","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","volume":"10","author":"ED Pagourelias","year":"2017","unstructured":"Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, Kuznetsova T, Voigt JU (2017) Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 10(3):e005588","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10062_CR65","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/heartjnl-2015-308657","volume":"102","author":"A Senapati","year":"2016","unstructured":"Senapati A, Sperry BW, Grodin JL, Kusunose K, Thavendiranathan P, Jaber W, Collier P, Hanna M, Popovic ZB, Phelan D (2016) Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart 102(10):748\u2013754","journal-title":"Heart"},{"issue":"10","key":"10062_CR66","first-page":"1128","volume":"18","author":"K Nochioka","year":"2017","unstructured":"Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH, Solomon SD (2017) Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 18(10):1128\u20131137","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10062_CR67","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/13506129.2018.1493989","volume":"25","author":"S Arvidsson","year":"2018","unstructured":"Arvidsson S, Henein MY, Wikstrom G, Suhr OB, Lindqvist P (2018) Right ventricular involvement in transthyretin amyloidosis. Amyloid 25(3):160\u2013166","journal-title":"Amyloid"},{"issue":"4","key":"10062_CR68","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","volume":"70","author":"A Martinez-Naharro","year":"2017","unstructured":"Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M (2017) Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol 70(4):466\u2013477","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10062_CR69","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","volume":"51","author":"H Vogelsberg","year":"2008","unstructured":"Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51(10):1022\u20131030","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10062_CR70","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","volume":"7","author":"M Fontana","year":"2014","unstructured":"Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2):157\u2013165","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1 Pt 1","key":"10062_CR71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","volume":"13","author":"A Baggiano","year":"2020","unstructured":"Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, Gritti M, Quarta C, Knight DS, Wechalekar AD, Lachmann HJ, Perlini S, Pontone G, Moon JC, Kellman P, Gillmore JD, Hawkins PN, Fontana M (2020) Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13(1 Pt 1):69\u201380","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4 Pt 1","key":"10062_CR72","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/0002-8703(82)90331-3","volume":"103","author":"TA Wizenberg","year":"1982","unstructured":"Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM (1982) Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 103(4 Pt 1):468\u2013473","journal-title":"Am Heart J"},{"issue":"5","key":"10062_CR73","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S0002-9149(83)80140-4","volume":"51","author":"RH Falk","year":"1983","unstructured":"Falk RH, Lee VW, Rubinow A, Hood WB Jr, Cohen AS (1983) Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 51(5):826\u2013830","journal-title":"Am J Cardiol"},{"issue":"6","key":"10062_CR74","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/archinte.1987.00370060035007","volume":"147","author":"MA Gertz","year":"1987","unstructured":"Gertz MA, Brown ML, Hauser MF, Kyle RA (1987) Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 147(6):1039\u20131044","journal-title":"Arch Intern Med"},{"issue":"9","key":"10062_CR75","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11886-019-1180-2","volume":"21","author":"L Chacko","year":"2019","unstructured":"Chacko L, Martone R, Cappelli F, Fontana M (2019) Cardiac amyloidosis: updates in imaging. Curr Cardiol Rep 21(9):108","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10062_CR76","first-page":"337","volume":"26","author":"O Bourogianni","year":"2019","unstructured":"Bourogianni O, Papadaki E, Foukarakis E, Koukouraki S (2019) Isolated cardiac amyloidosis. Utility of bone seeking tracers scintigraphy in differentiating the subtype of amyloid: a case report, J Nucl Cardiol 26(1):337\u2013341","journal-title":"Utility of bone seeking tracers scintigraphy in differentiating the subtype of amyloid: a case report, J Nucl Cardiol"},{"issue":"4","key":"10062_CR77","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","volume":"22","author":"A Galat","year":"2015","unstructured":"Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, Guendouz S, Tissot CM, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Itti E, Meignan M, Damy T (2015) Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 22(4):210\u2013220","journal-title":"Amyloid"},{"issue":"2","key":"10062_CR78","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195\u2013201","journal-title":"Circ Cardiovasc Imaging"},{"issue":"Suppl 1","key":"10062_CR79","first-page":"42","volume":"18","author":"V Papantoniou","year":"2015","unstructured":"Papantoniou V, Valsamaki P, Kastritis S, Tsiouris S, Delichas Z, Papantoniou Y, Tsiouma M, Athanasoulis T, Fotopoulos A, Dimopoulos MA (2015) Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy. Hell J Nucl Med 18(Suppl 1):42\u201350","journal-title":"Hell J Nucl Med"},{"issue":"6","key":"10062_CR80","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076\u20131084","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10062_CR81","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","volume":"45","author":"G Treglia","year":"2018","unstructured":"Treglia G, Glaudemans A, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, Ceriani L, Prior JO, Giovanella L, Slart R (2018) Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 45(11):1945\u20131955","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10062_CR82","first-page":"161","volume":"22","author":"PN Valsamaki","year":"2019","unstructured":"Valsamaki PN, Zissimopoulos A (2019) Cardiac amyloidosis. Two main subtypes and diagnosis by nuclear medicine: SPET tracer revival. Hell J Nucl Med 22(3):161\u2013164","journal-title":"Hell J Nucl Med"},{"issue":"6","key":"10062_CR83","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","volume":"4","author":"C Rapezzi","year":"2011","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F (2011) Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 4(6):659\u2013670","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10062_CR84","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans A, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart R, Verberne HJ, Bourque JM (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 26(6):2065\u20132123","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"10062_CR85","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s002590050406","volume":"26","author":"N Delahaye","year":"1999","unstructured":"Delahaye N, Dinanian S, Slama MS, Mzabi H, Samuel D, Adams D, Merlet P, Le Guludec D (1999) Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med 26(4):416\u2013424","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"10062_CR86","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0735-1097(96)00438-X","volume":"29","author":"M Tanaka","year":"1997","unstructured":"Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, Isobe M, Sekiguchi M (1997) Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 29(1):168\u2013174","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10062_CR87","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCIMAGING.112.000367","volume":"6","author":"MC Coutinho","year":"2013","unstructured":"Coutinho MC, Cortez-Dias N, Cantinho G, Conceicao I, Oliveira A, Bordalo e Sa A, Goncalves S, Almeida AG, de Carvalho M, Diogo AN, (2013) Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging 6(5):627\u201336","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"10062_CR88","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, Moore SC, Falk RH (2014) Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 41(9):1652\u20131662","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10062_CR89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fcvm.2015.00023","volume":"2","author":"DR Osborne","year":"2015","unstructured":"Osborne DR, Acuff SN, Stuckey A, Wall JS (2015) A routine PET\/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-florbetapir. Front Cardiovasc Med 2:23","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10062_CR90","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","volume":"57","author":"WP Law","year":"2016","unstructured":"Law WP, Wang WY, Moore PT, Mollee PN, Ng AC (2016) Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med 57(11):1733\u20131739","journal-title":"J Nucl Med"},{"issue":"2","key":"10062_CR91","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, Kero T, Langstrom B, Granstam SO, Rosengren S, Vedin O, Wassberg C, Wikstrom G, Westermark P, Sorensen J (2013) In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 54(2):213\u2013220","journal-title":"J Nucl Med"},{"issue":"1","key":"10062_CR92","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","volume":"8","author":"SP Lee","year":"2015","unstructured":"Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, Kwon JH, Paeng JC, Kim HK, Cheon GJ, Kim YJ, Kim I, Yoon SS, Seo JW, Sohn DW (2015) 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 8(1):50\u201359","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10062_CR93","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12350-018-01551-5","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Falk R (2019) Imaging cardiac amyloidosis: Patient page. J Nucl Cardiol 26(1):217\u2013221","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"10062_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/1097-0339(200103)24:3<181::AID-DC1037>3.0.CO;2-D","volume":"24","author":"CD Guy","year":"2001","unstructured":"Guy CD, Jones CK (2001) Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol 24(3):181\u2013185","journal-title":"Diagn Cytopathol"},{"issue":"14","key":"10062_CR95","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","volume":"125","author":"C Fernandez de Larrea","year":"2015","unstructured":"Fernandez de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, Milani P, Capello GL, Paulli M, Palladini G, Merlini G (2015) A practical approach to the diagnosis of systemic amyloidoses. Blood 125(14):2239\u20132244","journal-title":"Blood"},{"issue":"11","key":"10062_CR96","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/PAS.0b013e3182263d74","volume":"35","author":"AA Satoskar","year":"2011","unstructured":"Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A, Nadasdy T (2011) Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol 35(11):1685\u20131690","journal-title":"Am J Surg Pathol"},{"issue":"24","key":"10062_CR97","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A (2009) Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114(24):4957\u20134959","journal-title":"Blood"},{"issue":"2","key":"10062_CR98","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","volume":"25","author":"E Muchtar","year":"2018","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Dingli D, Rajkumar SV, Dispenzieri A, Grogan M (2018) Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 25(2):86\u201392","journal-title":"Amyloid"},{"key":"10062_CR99","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","volume":"133","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Sperry BW, Gabrovsek A, Ikram A, Tang WHW, Estep J, Hanna M (2020) Digoxin use in cardiac amyloidosis. Am J Cardiol 133:134\u2013138","journal-title":"Am J Cardiol"},{"issue":"4","key":"10062_CR100","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","volume":"6","author":"S Giancaterino","year":"2020","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC (2020) Management of Arrhythmias in Cardiac Amyloidosis. JACC Clin Electrophysiol 6(4):351\u2013361","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"10062_CR101","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.12308","volume":"5","author":"YY Mints","year":"2018","unstructured":"Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL (2018) Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail 5(5):772\u2013779","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10062_CR102","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","volume":"73","author":"EA El-Am","year":"2019","unstructured":"El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, Noseworthy PA, Lin G, Pislaru SV, Egbe AC, Grogan M, Nkomo VT (2019) Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 73(5):589\u2013597","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10062_CR103","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","volume":"116","author":"D Feng","year":"2007","unstructured":"Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed IS, Hughes DA, Lust JA, Jaffe AS, Gertz MA, Klarich KW (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420\u20132426","journal-title":"Circulation"},{"issue":"8","key":"10062_CR104","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.cardfail.2019.07.233","volume":"25","author":"LR Mitrani","year":"2019","unstructured":"Mitrani LR, De Los Santos J, Helmke S, Biviano AB, Maurer MS (2019) Anticoagulation with warfarin versus novel oral anticoagulants in atrial fibrillation in amyloid transthyretin amyloidosis cardiomyopathy: a retrospective cohort study. J Cardiac Fail 25(8):S82","journal-title":"J Cardiac Fail"},{"key":"10062_CR105","doi-asserted-by":"crossref","unstructured":"Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ, E.S.C.S.D. Group (2015) ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36(41):2793\u20132867","DOI":"10.1093\/eurheartj\/ehv316"},{"issue":"11","key":"10062_CR106","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/jce.14180","volume":"30","author":"E Donnellan","year":"2019","unstructured":"Donnellan E, Wazni OM, Saliba WI, Baranowski B, Hanna M, Martyn M, Patel D, Trulock K, Menon V, Hussein A, Aagaard P, Jaber W, Kanj M (2019) Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol 30(11):2427\u20132432","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"14","key":"10062_CR107","doi-asserted-by":"publisher","first-page":"e017335","DOI":"10.1161\/JAHA.120.017335","volume":"9","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Hanna M, Kanj M, Saliba WI, Jaber WA (2020) Cardiac resynchronization therapy for transthyretin cardiac amyloidosis. J Am Heart Assoc 9(14):e017335","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10062_CR108","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","volume":"20","author":"A Castano","year":"2015","unstructured":"Castano A, Drachman BM, Judge D, Maurer MS (2015) Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 20(2):163\u2013178","journal-title":"Heart Fail Rev"},{"issue":"24","key":"10062_CR109","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 109(24):9629\u20139634","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10062_CR110","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785\u201392","journal-title":"Neurology"},{"key":"10062_CR111","doi-asserted-by":"crossref","unstructured":"Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B (2020) Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: clinical trial results up to 8.5 years. Neurol Ther 9(1):105\u2013115","DOI":"10.1007\/s40120-020-00180-w"},{"issue":"6","key":"10062_CR112","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini G, Plante-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR (2013) Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 6(6):1011\u20131020","journal-title":"J Cardiovasc Transl Res"},{"issue":"3","key":"10062_CR113","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24(3):194\u2013204","journal-title":"Amyloid"},{"issue":"11","key":"10062_CR114","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"5","key":"10062_CR115","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/labinvest.3700059","volume":"84","author":"SR Miller","year":"2004","unstructured":"Miller SR, Sekijima Y, Kelly JW (2004) Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84(5):545\u2013552","journal-title":"Lab Invest"},{"issue":"24","key":"10062_CR116","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial C (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310(24):2658\u201367","journal-title":"JAMA"},{"issue":"45","key":"10062_CR117","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","volume":"40","author":"M Emdin","year":"2019","unstructured":"Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferovic PM, Barison A, Castiglione V, Vergaro G, Giannoni A, Passino C, Merlini G (2019) Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 40(45):3699\u20133706","journal-title":"Eur Heart J"},{"issue":"6","key":"10062_CR118","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","volume":"18","author":"A Castano","year":"2012","unstructured":"Castano A, Helmke S, Alvarez J, Delisle S, Maurer MS (2012) Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail 18(6):315\u2013319","journal-title":"Congest Heart Fail"},{"issue":"3","key":"10062_CR119","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","volume":"25","author":"A Ikram","year":"2018","unstructured":"Ikram A, Donnelly JP, Sperry BW, Samaras C, Valent J, Hanna M (2018) Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center\u2019s experience. Amyloid 25(3):197\u2013202","journal-title":"Amyloid"},{"key":"10062_CR120","doi-asserted-by":"crossref","unstructured":"Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL (2019) Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. J Card Fail","DOI":"10.1016\/j.cardfail.2019.11.024"},{"key":"10062_CR121","unstructured":"Griffin JM, Maurer MS (2019) Transthyretin cardiac amyloidosis: a treatable form of heart failure with a preserved ejection fraction. Trends Cardiovasc Med"},{"issue":"8","key":"10062_CR122","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1096\/fj.02-0764com","volume":"17","author":"I Cardoso","year":"2003","unstructured":"Cardoso I, Merlini G, Saraiva MJ (2003) 4\u2019-iodo-4\u2019-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J 17(8):803\u2013809","journal-title":"FASEB J"},{"issue":"9","key":"10062_CR123","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbadis.2008.05.005","volume":"1782","author":"B Macedo","year":"2008","unstructured":"Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ (2008) Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta 1782(9):517\u2013522","journal-title":"Biochim Biophys Acta"},{"key":"10062_CR124","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1479-5876-8-74","volume":"8","author":"I Cardoso","year":"2010","unstructured":"Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ (2010) Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 8:74","journal-title":"J Transl Med"},{"issue":"Suppl 1","key":"10062_CR125","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/13506129.2012.678508","volume":"19","author":"L Obici","year":"2012","unstructured":"Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G (2012) Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19(Suppl 1):34\u201336","journal-title":"Amyloid"},{"issue":"9","key":"10062_CR126","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369(9):819\u2013829","journal-title":"N Engl J Med"},{"key":"10062_CR127","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"OB Suhr","year":"2015","unstructured":"Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM, Bettencourt BR, Vaishnaw A, Gollob J, Adams D (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10062_CR128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"4","key":"10062_CR129","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431\u2013443","journal-title":"Circulation"},{"issue":"3","key":"10062_CR130","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, Kim TW, Jesse Kwoh T, Matson J, Norris D, Yu R, Watt A, Monia BP (2016) Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid 23(3):148\u2013157","journal-title":"Amyloid"},{"issue":"1","key":"10062_CR131","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"1","key":"10062_CR132","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD (2020) Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 27(1):52\u201358","journal-title":"Amyloid"},{"key":"10062_CR133","doi-asserted-by":"publisher","first-page":"25080","DOI":"10.1038\/srep25080","volume":"6","author":"NJ Galant","year":"2016","unstructured":"Galant NJ, Bugyei-Twum A, Rakhit R, Walsh P, Sharpe S, Arslan PE, Westermark P, Higaki JN, Torres R, Tapia J, Chakrabartty A (2016) Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses. Sci Rep 6:25080","journal-title":"Sci Rep"},{"issue":"17","key":"10062_CR134","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","volume":"61","author":"M Miller","year":"2018","unstructured":"Miller M, Pal A, Albusairi W, Joo H, Pappas B, Haque Tuhin MT, Liang D, JampalaR Liu F, Khan J, Faaij M, Park M, Chan W, Graef I, Zamboni R, Kumar N, Fox J, Sinha U, Alhamadsheh M (2018) Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem 61(17):7862\u20137876","journal-title":"J Med Chem"},{"issue":"5539","key":"10062_CR135","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1126\/science.1062245","volume":"293","author":"P Hammarstrom","year":"2001","unstructured":"Hammarstrom P, Schneider F, Kelly JW (2001) Trans-suppression of misfolding in an amyloid disease. Science 293(5539):2459\u20132462","journal-title":"Science"},{"issue":"3","key":"10062_CR136","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, Grogan M, Selby VN, Jacoby D, Hanna M, Nativi-Nicolau J, Patel J, Rao S, Sinha U, Turtle CW, Fox JC (2019) Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 74(3):285\u2013295","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10062_CR137","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, Andersen O, Karlberg I, Norden G, Nakazato M et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40(3):242\u2013246","journal-title":"Clin Genet"},{"issue":"9","key":"10062_CR138","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99(9):1847\u20131854","journal-title":"Transplantation"},{"issue":"1","key":"10062_CR139","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","volume":"7","author":"M Yazaki","year":"2007","unstructured":"Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, Kawamorita A, Kanno H, Ikeda SI (2007) Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 7(1):235\u2013242","journal-title":"Am J Transplant"},{"issue":"1","key":"10062_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","volume":"35","author":"Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A, International Society for Heart Lung Transplantation Infectious Diseases P, Heart F, Transplantation C","year":"2016","unstructured":"Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A, International Society for Heart Lung Transplantation Infectious Diseases P, Heart F, Transplantation C (2016) The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 35(1):1\u201323","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10062_CR141","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/TP.0b013e3181ac60db","volume":"88","author":"E Raichlin","year":"2009","unstructured":"Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, Clavell AL, Rodeheffer RJ, Pereira NL, Kremers WK, Kushwaha SS, Edwards BS (2009) Combined heart and liver transplantation: a single-center experience. Transplantation 88(2):219\u2013225","journal-title":"Transplantation"},{"issue":"11","key":"10062_CR142","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1097\/TP.0000000000002240","volume":"102","author":"AN Rosenbaum","year":"2018","unstructured":"Rosenbaum AN, AbouEzzeddine OF, Grogan M, Dispenzieri A, Kushwaha S, Clavell A, Daly RC, Edwards BS (2018) Outcomes after cardiac transplant for wild type transthyretin amyloidosis. Transplantation 102(11):1909\u20131913","journal-title":"Transplantation"},{"issue":"1","key":"10062_CR143","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12968-018-0478-3","volume":"20","author":"F Ridouani","year":"2018","unstructured":"Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, Audureau E, Bodez D, Rahmouni A, Deux JF (2018) Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson 20(1):58","journal-title":"J Cardiovasc Magn Reson"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10062-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-10062-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10062-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T15:29:17Z","timestamp":1666798157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-10062-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":143,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10062"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-10062-w","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"30 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Bistola reports honoraria for lectures from Novartis, Pfizer, and Servier. Dr. Parissis reports horonaria for lectures and advisory boards from Novartis, Pfizer, Servier, Orion Pharma, and Roche Diagnostics. Dr. Kastritis has received honoraria for lectures and advisory boards from Amgen, Genesis Pharma, Janssen, Takeda, Pfizer, and research funding from Amgen and Janssen. Dr. Foukarakis reports honoraria for lectures and advisory boards from Pfizer, Menarini and Bayer. G. Koutsis has received research grants from Genesis Pharma and Teva, consultation fees, advisory boards, and honoraria from Genzyme, Genesis Pharma, Teva, and Novartis. Drs. Valsamaki, Anastasakis, and Efthimiadis report honoraria from Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors agree to publish the present manuscript in its current form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}